008930:KRXHanmi Science Co., Ltd Analysis

Hanmi Science trades well above its 20‑day SMA, which sits just above the 50‑day SMA, while the MACD line remains below its signal, indicating bearish momentum. The RSI hovers in the mid‑40s, suggesting the stock is not overbought but also lacks strong buying pressure. Volume trend is decreasing, hinting at waning participation, and the 30‑day volatility is approaching 100%, pointing to sizable price swings. A beta below 0.5 reflects lower systematic risk relative to the market. A DCF fair‑value estimate is far below the current price, implying the stock is overvalued. The balance sheet shows a high debt‑to‑equity ratio, raising concerns about leverage. Dividend yield is under 1% with a modest payout ratio, which appears sustainable given strong cash flow. Overall, the stock appears priced for risk, with limited upside in the near term.
Given these technical and valuation signals, a short‑term hold is prudent while monitoring volume and any earnings updates. The medium‑term stance remains neutral, supported by steady revenue growth and cash flow but tempered by leverage. For the long horizon, the overvaluation and debt profile suggest a sell outlook unless a catalyst re‑prices the risk.